BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 36206404)

  • 1. Development of T-cell engagers selective for cells co-expressing two antigens.
    Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
    MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
    Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
    J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
    Dang K; Castello G; Clarke SC; Li Y; Balasubramani A; Boudreau A; Davison L; Harris KE; Pham D; Sankaran P; Ugamraj HS; Deng R; Kwek S; Starzinski A; Iyer S; van Schooten W; Schellenberger U; Sun W; Trinklein ND; Buelow R; Buelow B; Fong L; Dalvi P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a novel T cell-engaging bispecific antibody for elimination of L1CAM-positive tumors.
    Yuan Y; Li J; Chen J; Han L; Wang L; Yue Y; Liu J; Zhang B; Yuan Y; Wu M; Bian Y; Xie Y; Zhu J
    Biomed Pharmacother; 2024 May; 174():116565. PubMed ID: 38603888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma.
    Yoneyama T; Kim MS; Piatkov K; Wang H; Zhu AZX
    PLoS Comput Biol; 2022 Jul; 18(7):e1009715. PubMed ID: 35839267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities.
    Baeuerle PA; Wesche H
    Curr Opin Oncol; 2022 Sep; 34(5):552-558. PubMed ID: 35880455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
    Caracciolo D; Riillo C; Ballerini A; Gaipa G; Lhermitte L; Rossi M; Botta C; Duroyon E; Grillone K; Gallo Cantafio ME; Buracchi C; Alampi G; Gulino A; Belmonte B; Conforti F; Golino G; Juli G; Altomare E; Polerà N; Scionti F; Arbitrio M; Iannone M; Martino M; Correale P; Talarico G; Ghelli Luserna di Rorà A; Ferrari A; Concolino D; Sestito S; Pensabene L; Giordano A; Hildinger M; Di Martino MT; Martinelli G; Tripodo C; Asnafi V; Biondi A; Tagliaferri P; Tassone P
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
    Miao G; Sun X
    Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
    de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
    Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific T-cell engagers for treatment of multiple myeloma.
    Ravi G; Costa LJ
    Am J Hematol; 2023 Mar; 98 Suppl 2():S13-S21. PubMed ID: 35702871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model.
    Zorn JA; Wheeler ML; Barnes RM; Kaberna J; Morishige W; Harris M; Huang RY; Lohre J; Chang YC; Chau B; Powers K; Schindler I; Neradugomma N; Thomas W; Liao X; Zhou Y; West SM; Wang F; Kotapati S; Chen G; Yamazoe S; Kosenko A; Dollinger G; Sproul T; Rajpal A; Strop P
    Sci Rep; 2022 Mar; 12(1):3530. PubMed ID: 35241687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
    Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
    J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]   [Full Text] [Related]  

  • 16. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. eIg-based bispecific T-cell engagers targeting EGFR: Format matters.
    Kühl L; Schäfer AK; Kraft S; Aschmoneit N; Kontermann RE; Seifert O
    MAbs; 2023; 15(1):2183540. PubMed ID: 36864566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release.
    Aschmoneit N; Kühl L; Seifert O; Kontermann RE
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34782429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
    Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors.
    Yoon A; Lee S; Lee S; Lim S; Park YY; Song E; Kim DS; Kim K; Lim Y
    Biomolecules; 2020 Mar; 10(3):. PubMed ID: 32143496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.